The goal of the PES Project is to Write and submit the EUROSTARS applicaiton within the deadline of 28th Febraury 2019.
The goal of this project is to start the Development of a new treatment for chronic lymphocytic leukemia (CLL). The primary objective of this project is to complete a phase 1 study with the new alpha-particle emitting radioimmunoconjugate 212Pb-TCMC-NNV003. The anti-CD37 radioimmunoconjugate 212Pb-TCMC-NNV003 consists of the anti-CD37 antibody NNV003 that is conjugated with the chelator TCMC that chelate the radionuclide lead-212. CLL is an incurable type of cancer. There is a medical need for a new treatment against this disease. An alpha-particle emitting radionuclide will be the ideal payload for an antibody targeted against a B-cell specific antigen like CD37. The patients develop resistance against the current treatments or the tumor relapse. Therefore, treatments against new targets are necessary. We have very promising results from preclinical studies and now we want to take this product candidate forward to clinical studies. The development has been performed in collaboration with the French company OranoMed (previously ArevaMed) and we plan to continue this Collaboration in this Project.